Mod­er­na wants an ac­cel­er­at­ed ap­proval for its can­cer vac­cine — but it's wait­ing on three things

Mod­er­na has tout­ed the pos­si­bil­i­ty of an ac­cel­er­at­ed ap­proval for its Mer­ck-part­nered can­cer vac­cine by 2025. But ac­cord­ing to ex­ec­u­tives, three things need to hap­pen first.

Mer­ck and Mod­er­na made news in De­cem­ber 2022 when they un­veiled Phase II da­ta sug­gest­ing their in­di­vid­u­al­ized neoanti­gen ther­a­py, or INT, re­duced the risk of can­cer re­cur­rence or death in melanoma pa­tients when used with Mer­ck’s Keytru­da. The da­ta rein­vig­o­rat­ed a field that has frus­trat­ed sci­en­tists for years. The ther­a­py is now in two Phase III tri­als in ad­ju­vant melanoma and non-small cell lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER